Achilles Therapeutics Explores Strategic Options Amid Financial Update
Company Announcements

Achilles Therapeutics Explores Strategic Options Amid Financial Update

Achilles Therapeutics (ACHL) has released an update.

Achilles Therapeutics has reported a cash position of $86.1 million as of September 30, 2024, with an additional $12.8 million received as a cash R&D tax credit in October. The company is seeking strategic options with BofA Securities following the discontinuation of its TIL-based cNeT program. Financial highlights reveal a net loss of $19.6 million for the third quarter, reflecting increased R&D expenses compared to the previous year.

For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyAchilles Therapeutics reports Q3 EPS (48c) vs. (42c) last year
Carrie WilliamsACHL Upcoming Earnings Report: What to Expect?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App